

PART 3	Standalone Information	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Current Year ended	Previous Year ended
		31.03.13 (AUDITED)	31.12.2012 (UNAUDITED)	31.3.2012 (AUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)
	PARTICULARS					
	Revenue	5,842.89	4,951.90	4,158.44	19,646.88	15,654.54
	Profit Before Tax from Ordinary activities	2,703.15	790.36	(11,988.13)	2,960.50	(18,290.29)
	Profit After Tax from Ordinary activities	3,700.92	790.36	(11,804.44)	3,958.27	(18,106.60)
	Profit After Tax after extraordinary item	3,700.92	790.36	(11,804.44)	3,958.27	(18,106.60)

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 27.05.2013.
- As per the audited Balance Sheet as at 31 March, 2011, the Company's Net Worth had been completely eroded. Therefore, as required under Section 15(1) of the SICA 1985, the Company has made a reference to the Board for Industrial and Financial Reconstruction (BIFR). Due to settlement of the substantial amount of the FCCBs and improved financial performance of the Company, the Net Worth of the Company has turned positive as at 31 March, 2013. Under the circumstances, the Company will seek withdrawal of its reference and will await necessary directives from the BIFR.
- The Company has settled / entered into settlement agreement with the FCCB holders for USD 48,789,000 worth of FCCBs in principal value out of USD 50,000,000 FCCBs issued initially. Under the settlement agreement, the settlement payout will be made over a period of 12 months for which adequate provisions have been made in the books of accounts.
- The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- The figure for the quarter ended March 31, 2013 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2013 and the unaudited published year to date figures up to December 31, 2012 being the date of the end of the third quarter of the financial year.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- Statement of Assets and Liabilities:

		₹ in Lakhs	
		As at March 31 (Audited)	
		2013	2012
A	EQUITY AND LIABILITIES		
	Shareholders' funds		
	(a) Share capital	5,203.07	5,028.07
	(b) Reserves and surplus	3,444.80	(21,951.02)
	(c) Money received against share warrants	-	115.66
	Sub-total-Shareholders' funds	8,647.87	(16,807.29)
	Minority Interest	699.00	561.61
	Non-current liabilities		
	(a) Long-term borrowings	787.68	1,520.14
	(b) Deferred tax liabilities (Net)	261.64	1,306.05
	Sub-total - Non-current liabilities	1,049.32	2,826.18
4	Current liabilities		
	(a) Short-term borrowings	11,378.70	11,392.25
	(b) Trade payables	5,606.16	5,861.80
	(c) Other current liabilities	10,873.44	33,639.34
	(d) Short-term provisions	1,869.96	1,032.48
	Sub-total -Current liabilities	29,728.26	51,925.87
	TOTAL-EQUITY AND LIABILITIES	40,124.45	38,506.38
B	ASSETS		
	Non-current assets		
	(a) Fixed assets	15,611.63	16,535.34
	(b) Non-current investments	-	-
	(c) Long-term loans and advances	120.21	408.27
	Sub-total - Non-current assets	15,731.84	16,943.61
	Current assets		
	(a) Inventories	7,769.19	7,335.89
	(b) Trade receivables	13,131.42	11,276.87
	(c) Cash and cash equivalents	1,588.00	2,238.66
2	(d) Short-term loans and advances	1,904.00	711.35
	(e) Other current assets- Miscellaneous expenditure	-	-
	Sub-total - Current assets	24,392.61	21,562.77
	TOTAL ASSETS	40,124.45	38,506.38

For MARKSANS PHARMA LIMITED



Place: Mumbai.
Date: 27.05.2013

[Signature]
MARK SALDANHA
Managing Director.